These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 7768627)

  • 1. Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection.
    Mallett CP; Hale TL; Kaminski RW; Larsen T; Orr N; Cohen D; Lowell GH
    Infect Immun; 1995 Jun; 63(6):2382-6. PubMed ID: 7768627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models.
    Orr N; Robin G; Cohen D; Arnon R; Lowell GH
    Infect Immun; 1993 Jun; 61(6):2390-5. PubMed ID: 8500877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal immunoglobulin A antibody directed against serotype-specific epitope of Shigella flexneri lipopolysaccharide protects against murine experimental shigellosis.
    Phalipon A; Kaufmann M; Michetti P; Cavaillon JM; Huerre M; Sansonetti P; Kraehenbuhl JP
    J Exp Med; 1995 Sep; 182(3):769-78. PubMed ID: 7544397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
    Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D
    Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody and cytokine responses in a mouse pulmonary model of Shigella flexneri serotype 2a infection.
    van de Verg LL; Mallett CP; Collins HH; Larsen T; Hammack C; Hale TL
    Infect Immun; 1995 May; 63(5):1947-54. PubMed ID: 7729907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of recombinant vaccine candidate molecule against Shigella infection.
    Chitradevi STS; Kaur G; Sivaramakrishna U; Singh D; Bansal A
    Vaccine; 2016 Oct; 34(44):5376-5383. PubMed ID: 27591952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.
    Cohen D; Orr N; Robin G; Slepon R; Ashkenazi S; Ashkenazi I; Shemer J
    Clin Diagn Lab Immunol; 1996 Jul; 3(4):451-5. PubMed ID: 8807212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of
    Turbyfill KR; Clarkson KA; Vortherms AR; Oaks EV; Kaminski RW
    mSphere; 2018; 3(2):. PubMed ID: 29600284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
    Oaks EV; Turbyfill KR
    Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection of adult rabbits and monkeys from lethal shigellosis by oral immunization with a thymine-requiring and temperature-sensitive mutant of Shigella flexneri Y.
    Ahmed ZU; Sarker MR; Sack DA
    Vaccine; 1990 Apr; 8(2):153-8. PubMed ID: 2186582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of anti-Shigella lipopolysaccharide (LPS) response by addition of the cholera toxin B subunit to oral and intranasal proteosome-Shigella flexneri 2a LPS vaccines.
    Orr N; Arnon R; Rubin G; Cohen D; Bercovier H; Lowell GH
    Infect Immun; 1994 Nov; 62(11):5198-200. PubMed ID: 7927807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection.
    Altboum Z; Barry EM; Losonsky G; Galen JE; Levine MM
    Infect Immun; 2001 May; 69(5):3150-8. PubMed ID: 11292735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shigella outer membrane protein PSSP-1 is broadly protective against Shigella infection.
    Kim JO; Rho S; Kim SH; Kim H; Song HJ; Kim EJ; Kim RY; Kim EH; Sinha A; Dey A; Yang JS; Song MK; Nandy RK; Czerkinsky C; Kim DW
    Clin Vaccine Immunol; 2015 Apr; 22(4):381-8. PubMed ID: 25651919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral immunization of monkeys with polyvalent dysentery vaccine.
    Dhikidze EK; Kavtaradze KN; Krilova RI; Rauss K; Kétyi I; Vertényi A
    Acta Microbiol Acad Sci Hung; 1977; 24(1):7-12. PubMed ID: 412396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.
    Ashkenazi S; Passwell JH; Harlev E; Miron D; Dagan R; Farzan N; Ramon R; Majadly F; Bryla DA; Karpas AB; Robbins JB; Schneerson R
    J Infect Dis; 1999 Jun; 179(6):1565-8. PubMed ID: 10228084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G.
    Clarkson KA; Frenck RW; Dickey M; Suvarnapunya AE; Chandrasekaran L; Weerts HP; Heaney CD; McNeal M; Detizio K; Parker S; Hoeper A; Bourgeois AL; Porter CK; Venkatesan MM; Kaminski RW
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32968012
    [No Abstract]   [Full Text] [Related]  

  • 17. Parameters underlying successful protection with live attenuated mutants in experimental shigellosis.
    Bernardini ML; Arondel J; Martini I; Aidara A; Sansonetti PJ
    Infect Immun; 2001 Feb; 69(2):1072-83. PubMed ID: 11160004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model.
    Yagnik B; Sharma D; Padh H; Desai P
    Vaccine; 2019 May; 37(23):3097-3105. PubMed ID: 31047673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
    Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R;
    Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains.
    Mel D; Gangarosa EJ; Radovanovic ML; Arsic BL; Litvinjenko S
    Bull World Health Organ; 1971; 45(4):457-64. PubMed ID: 4948417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.